免疫检查点抑制剂治疗与患黑色素瘤脑转移的风险降低有关
Anna Fager1,2, Matilda Samuelsson3, Roger Olofsson Bagge4,5
1Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. anna.fager@gu.se.
BJC reports
|April 11, 2025
概括
免疫检查点抑制剂 (ICI) 显著降低了黑色素瘤脑转移 (MBM) 的风险. 在晚期黑色素瘤患者中,S100B水平升高和第四阶段疾病增加了MBM风险.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 神经瘤学神经瘤学
背景情况:
- 尽管治疗进展,黑色素瘤脑转移 (MBM) 仍然是一个重大的临床挑战.
- 了解影响MBM发展的因素对于风险分层和预防至关重要.
研究的目的:
- 确定与晚期黑色素瘤患者的MBM发展相关的临床,突变和生物标记因子.
- 评估一线治疗对MBM发病率的影响.
主要方法:
- 对395名在2013-2019年期间诊断出晚期黑色素瘤患者 (III-IV阶段) 的回顾性分析.
- 单变量和多变量考克斯回归分析了基线特征,瘤状况,生物标志物和一线治疗.
- 开发了MBM (BM+) 和那些没有 (BM-) 的患者之间的比较.
主要成果:
- 在395名患者中,有91名患者发展为MBM.
- 一线免疫检查点抑制剂 (ICI) 治疗与MBM显著降低的风险相关 (p≤0.001).
- 血S100B水平升高和更高的转移阶段与增加的MBM风险相关.
结论:
- 治疗ICI证明了对MBM发展的保护作用.
- 高S100B水平和诊断时的第四阶段疾病是增加MBM风险的潜在指标.
- 对ICI机制和风险分层生物标志物的进一步研究是有必要的.
相关概念视频
01:27Tumor Immunotherapy
406
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
406
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K